Yoshinobu Nakamaru

发表

Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules

M. Shimizu, H. Yamazaki, R. Saito, 2016, Biopharmaceutics & drug disposition.

A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects

H. Shimizu, Yoshinobu Nakamaru, K. Kondo, 2020, Clinical pharmacology in drug development.

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment.

Yoshinobu Nakamaru, K. Kondo, M. Akimoto, 2020, Clinical therapeutics.

Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations

Koji Takei, J. Palumbo, Yoshinobu Nakamaru, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Mechanistic evaluation of the effect of sodium‐dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics

R. Saito, Y. Tashima, Yoshinobu Nakamaru, 2020, Biopharmaceutics & drug disposition.

Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.

Yoshinobu Nakamaru, Noriko Hisanaga, K. Akimoto, 2015, Clinical therapeutics.

Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.

H. Yamazaki, Yoshinobu Nakamaru, K. Akimoto, 2014, Clinical Therapeutics.

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

H. Yamazaki, R. Ikegawa, Yoshinobu Nakamaru, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

H. Utsumi, S. Kiuchi, Yoshinobu Nakamaru, 2012, Bioorganic & medicinal chemistry.

Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors

Yoshinobu Nakamaru, Noriko Hisanaga, T. Kume, 2016, Biopharmaceutics & drug disposition.

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

M. Hirai, H. Shimizu, Yoshinobu Nakamaru, 2021, Clinical pharmacology in drug development.

Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults

H. Shimizu, Yoshinobu Nakamaru, K. Kondo, 2021, Clinical pharmacology in drug development.

Mechanosensitive channel functions to alleviate the cell lysis of marine bacterium, Vibrio alginolyticus, by osmotic downshock

Tatsunosuke Nakamura, T. Unemoto, Yoshinobu Nakamaru, 1999, FEBS letters.

Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals

H. Yamazaki, H. Shimizu, Yoshinobu Nakamaru, 2018, Drug Metabolism and Disposition.

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

S. Kiuchi, Yoshinobu Nakamaru, K. Ueta, 2015, Journal of pharmacological sciences.

Human pharmacokinetic profiling of the dipeptidyl peptidase‐IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling

Hiroshi Yamazaki, Chie Emoto, M. Shimizu, 2015, Biopharmaceutics & drug disposition.

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

H. Utsumi, S. Kiuchi, Yoshinobu Nakamaru, 2012, Bioorganic & medicinal chemistry.

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

S. Kiuchi, Yoshinobu Nakamaru, K. Ueta, 2015, Journal of pharmacological sciences.

Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.

Yoshinobu Nakamaru, K. Kondo, V. Todorovic, 2020, Clinical therapeutics.